181 related articles for article (PubMed ID: 38486123)
1. Functional proteomics of colon cancer Consensus Molecular Subtypes.
Feliu J; Gámez-Pozo A; Martínez-Pérez D; Pérez-Wert P; Matamala-Luengo D; Viñal D; Kunz L; López-Vacas R; Dittmann A; Rodríguez-Salas N; Custodio A; Fresno Vara JÁ; Trilla-Fuertes L
Br J Cancer; 2024 Jun; 130(10):1670-1678. PubMed ID: 38486123
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic subtypes predict outcomes in colorectal cancer.
Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
[TBL] [Abstract][Full Text] [Related]
3. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
4. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
[TBL] [Abstract][Full Text] [Related]
5. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
[TBL] [Abstract][Full Text] [Related]
6. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
Pilati C; Taieb J; Balogoun R; Marisa L; de Reyniès A; Laurent-Puig P
Ann Oncol; 2017 May; 28(5):1032-1035. PubMed ID: 28328000
[TBL] [Abstract][Full Text] [Related]
7. Consensus molecular subtype classification of colorectal adenomas.
Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
[TBL] [Abstract][Full Text] [Related]
8. Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.
Dunne PD; O'Reilly PG; Coleman HG; Gray RT; Longley DB; Johnston PG; Salto-Tellez M; Lawler M; McArt DG
Oncotarget; 2016 Jun; 7(24):36632-36644. PubMed ID: 27153559
[TBL] [Abstract][Full Text] [Related]
9. A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier.
Shinto E; Oki E; Shimokawa M; Yamaguchi S; Ishiguro M; Morita M; Kusumoto T; Tomita N; Hashiguchi Y; Tanaka M; Ohnuma S; Tada S; Matsushima T; Hase K
Oncology; 2020; 98(8):534-541. PubMed ID: 32235113
[TBL] [Abstract][Full Text] [Related]
10. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
[TBL] [Abstract][Full Text] [Related]
11. Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study.
González-Montero J; Burotto M; Valenzuela G; Mateluna D; Buen-Abad F; Toro J; Barajas O; Marcelain K
World J Clin Oncol; 2023 Oct; 14(10):409-419. PubMed ID: 37970108
[TBL] [Abstract][Full Text] [Related]
12. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
[TBL] [Abstract][Full Text] [Related]
13. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
[TBL] [Abstract][Full Text] [Related]
14. Interconnectivity between molecular subtypes and tumor stage in colorectal cancer.
Coebergh van den Braak RRJ; Ten Hoorn S; Sieuwerts AM; Tuynman JB; Smid M; Wilting SM; Martens JWM; Punt CJA; Foekens JA; Medema JP; IJzermans JNM; Vermeulen L
BMC Cancer; 2020 Sep; 20(1):850. PubMed ID: 32887573
[TBL] [Abstract][Full Text] [Related]
15. Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Huerta M; Roselló S; Zuniga S; Calon A; Carbonell-Asins JA; Fontana E; Martinez-Ciarpaglini C; Eason K; Rentero-Garrido P; Fleitas T; Papaccio F; Moro-Valdezate D; Nyamundanda G; Castillo J; Espí A; Sadanandam A; Roda D; Cervantes A
ESMO Open; 2020 Sep; 5(5):e000847. PubMed ID: 32967918
[TBL] [Abstract][Full Text] [Related]
16. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy in resected colon cancer: When, how and how long?
Gelibter AJ; Caponnetto S; Urbano F; Emiliani A; Scagnoli S; Sirgiovanni G; Napoli VM; Cortesi E
Surg Oncol; 2019 Sep; 30():100-107. PubMed ID: 31500770
[TBL] [Abstract][Full Text] [Related]
18. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
19. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.
Linnekamp JF; Hooff SRV; Prasetyanti PR; Kandimalla R; Buikhuisen JY; Fessler E; Ramesh P; Lee KAST; Bochove GGW; de Jong JH; Cameron K; Leersum RV; Rodermond HM; Franitza M; Nürnberg P; Mangiapane LR; Wang X; Clevers H; Vermeulen L; Stassi G; Medema JP
Cell Death Differ; 2018 Mar; 25(3):616-633. PubMed ID: 29305587
[TBL] [Abstract][Full Text] [Related]
20. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
[No Abstract] [Full Text] [Related]
[Next] [New Search]
